| Safety and efficacy of everolimus (EVE) as second–line treatment in neuroendocrine neoplasms G3 (NEN G3) - an AIO phase II study (EVINEC) |
|
|
| Oncol Res Treat 47 (suppl 1): 236 |
|
2024 |
|
Neuroendokrine Tumoren
|
|
|
| doi.org/10.1159/000535363 |
|
|
| AIO-BNHO Comprehensive clinico-genomics database network (CONNECT, AIO-TF-0122) in Germany. |
|
|
| Oncol Res Treat 47(suppl 2): 201 |
|
2024 |
|
Molekulare und translationale Onkologie
|
|
|
| doi.org/10.1159/000540557 |
|
|
| mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: Discovery and validation of a gene expression signature in three randomized trials. |
|
|
| Ann Oncol 35 (Supplement 2, 581P): 471 |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2024.08.650 |
|
|
| mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). |
|
|
| ESMO Open 9 (9) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.esmoop.2024.103703 |
|
|
| Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO. |
|
|
| Ann Oncol 35 (Supplement 2, 506O): 430-1 |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| doi.org/10.1016/j.annonc.2024.08.575 |
|
|
| Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212). |
|
|
| J Clin Oncol 41 (suppl 4) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2023.41.4_suppl.51 |
|
|
| Combined amphiregulin and epiregulin expression as a prognostic and predictive biomarker of panitumumab (Pmab), fluorouracil, and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212). |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3528 |
|
|
| t. Dermatology-related quality of life outcomes in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with fluorouracil and folinic acid with or without panitumumab (Pmab) maintenance after FOLFOX + Pmab induction: A prespecified secondary analysis of the phase 2 randomized PanaMa (AIO KRK 0212) trial |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e15539 |
|
|
| FU/FA maintenance therapy with or without panitumumab (pmab) in RAS wild-type metastatic colorectal cancer (mCRC) (PanaMa, AIO KRK 0212): Updated efficacy analyses. |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.3506 |
|
|
| Spatial patterns in the tumor immune microenvironment as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab+FOLFOX induction in RAS wildtype (wt) metastatic colorectal cancer (mCRC): PanaMa (AIO KRK0212) trial |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.3539 |
|
|
